Azithromycin 1.5 ophthalmic solution: In purulent bacterial or trachomatous conjunctivitis

Drugs

Volumn 72, Issue 3, 2012, Pages 361-373

  Garnock Jones, Karly P ^a  

^a Adis ^*  (New Zealand)

Author keywords

Adis Drug Profiles; Azithromycin; Infectious conjunctivitis; Ophthalmic; Trachoma

Indexed keywords

AZITHROMYCIN; TOBRAMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; BACTERIUM CULTURE; BLURRED VISION; CHLAMYDIA TRACHOMATIS; CONJUNCTIVITIS; CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; EMBASE; EYE BURNING; EYE DISCHARGE; HAEMOPHILUS INFLUENZAE; HUMAN; INTRAOCULAR FOREIGN BODY; MEDLINE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OCULAR PRURITUS; PURULENT BACTERIAL CONJUNCTIVITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REVIEW; SINGLE DRUG DOSE; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCUS PNEUMONIAE; TRACHOMA;

ANIMALS; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CHLAMYDIA TRACHOMATIS; HAEMOPHILUS INFLUENZAE; HUMANS; OPHTHALMIC SOLUTIONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; TRACHOMA; TREATMENT OUTCOME;

BACTERIA (MICROORGANISMS); CHLAMYDIA; CHLAMYDIA TRACHOMATIS; HAEMOPHILUS INFLUENZAE;

EID: 84856694150     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11208580-000000000-00000     Document Type: Review

References (25)

1. Hoøvding G. Acute bacterial conjunctivitis. Acta Ophthalmol 2008 Feb; 86 (1): 5-17 (Pubitemid 351512464)
2. Tarabishy AB, Jeng BH. Bacterial conjunctivitis: a review for internists. Cleve Clin J Med 2008 Jul; 75 (7): 507-12
3. Mathew AA, Turner A, Taylor HR. Strategies to control trachoma. Drugs 2009 May 29; 69 (8): 953-70
4. Bré mond-GignacD, Chiambaretta F,Milazzo S. A European perspective on topical ophthalmic antibiotics: current and evolving options. Ophthalmol Eye Dis 2011; 3: 29-43
5. Bré mond-Gignac D, Mariani-Kurkdjian P, Beresniak A, et al. Efficacy and safety of azithromycin 1.5% eye drops for purulent bacterial conjunctivitis in pediatric patients. Pediatr Infect Dis J 2010 Mar; 29 (3): 222-6
6. Denis F, Chaumeil C, Goldschmidt P, et al. Microbiological efficacy of 3-day treatment with azithromycin 1.5% eyedrops for purulent bacterial conjunctivitis. Eur J Ophthalmol 2008 Nov 31; 18 (6): 858-68
7. Spectrum Thea Pharmaceuticals Ltd. Azyter- (azithromycin dihydrate 1.5% ophthalmic solution): summary of product characteristics [online]. Available from URL: http://www.medicines.org.uk/EMC/medicine/24743/SPC/Azyter/[Accessed 2012 Jan 9]
8. Asbell PA, Colby KA, Deng S, et al. Ocular TRUST: nationwide antimicrobial susceptibility patterns in ocular isolates. Am J Ophthalmol 2008 Jun; 145 (6): 951-8
9. Ohnsman C, Ritterband D, O'Brien T, et al. Comparison of azithromycin and moxifloxacin against bacterial isolates causing conjunctivitis. Curr Med Res Opin 2007 Sep; 23 (9): 2241-9 (Pubitemid 350246610)
10. Haas W, Pillar CM, Torres M, et al. Monitoring antibiotic resistance in ocular microorganisms: results from the Antibiotic Resistance Monitoring in Ocular micRorganisms (ARMOR) 2009 surveillance study. Am J Ophthalmol 2011 Oct; 152 (4): 567-74.e3
11. Hong KC, Schachter J, Moncada J, et al. Lack of macrolide resistance in Chlamydia trachomatis after mass azithromycin distributions for trachoma. Emerg Infect Dis 2009; 15 (7): 1088-90
12. Swainston Harrison T, Keam SJ. Azithromycin extended release: a review of its use in the treatment of acute bacterial sinusitis and community-acquired pneumonia in the US. Drugs 2007; 67 (5): 773-92 (Pubitemid 46540290)
13. Garcia-Layana A. Anti-inflammatory effects of the azithromycin1.5% eye drops (Azyter) (animal model) [abstract no. 185 plus oral presentation]. 11th International Ocular Inflammation Society Congress and International Assembly of Ocular Inflammation Societies; 2011 Nov 13-16; Benaulim
14. Mencucci R, Paladini I, Favuzza E, et al. Azithromycin: intrinsic cytotoxic effects on corneal epithelial cell cultures [abstract no. 1499/D897]. The Association for Research in Vision and Ophthalmology; 2011 May 1-5; Fort Lauderdale (FL)
15. Chiambaretta F, Garraffo R, Elena PP, et al. Tear concentrations of azithromycin following topical administration of a single dose of azithromycin 0.5%, 1.0%, and 1.5% eyedrops (T1225) in healthy volunteers. Eur J Ophthalmol 2008 Jan 28; 18 (1): 13-20 (Pubitemid 351428543)
16. Goldschmidt PL, Chiambaretta F, Garraffo R, et al. Tear concentrations of azithromycin (AZM) following a single instillation and a bid dosing regimen for 3 days of T12250.5%, 1.0% and 1.5% eye-drops [abstract no. 773/B548]. The Association for Research in Vision and Ophthalmology; 2007 May 6-10; Fort Lauderdale (FL)
17. Amar T, Caillaud T, Elena P-P. Ocular pharmacokinetic study following single and multiple azithromycin administrations in pigmented rabbits. Curr Eye Res 2008; 33 (2): 149-58 (Pubitemid 351302201)
18. Tabbara KF, Kotb AA, Hammouda EF, et al. Effects of dehydration on corneal tissue absorption of topical azithromycin in rabbits. Curr Eye Res 2005 Oct; 30 (10): 915-8 (Pubitemid 43154710)
19. Cochereau I, Meddeb-Ouertani A, Khairallah M, et al. 3-day treatment with azithromycin 1.5% eye drops versus 7-day treatment with tobramycin 0.3% for purulent bacterial conjunctivitis: multicentre, randomised and controlled trial in adults and children. Br J Ophthalmol 2007 Apr; 91 (4): 465-9 (Pubitemid 46623678)
20. Cochereau I, Goldschmidt P, Goepogui A, et al. Efficacy and safety of short duration azithromycin eye drops versus azithromycin single oral dose for the treatment of trachoma in children: a randomised, controlled, double-masked clinical trial. Br J Ophthalmol 2007 May; 91 (5): 667-72 (Pubitemid 46716540)
21. Ambroziak AM, Szaflik JP, Hapunik A. Evaluation of effectiveness and tolerance of treatment with azithromycin 1.5% eye drops in bacterial conjunctivitis [in Polish]. Klin Oczna 2009; 111 (1-3): 46-9
22. Amza A, Goldschmidt P, Einterz E, et al. Elimination of active trachoma after two topical mass treatments with azithromycin 1.5% eye drops. PLoS Negl Trop Dis 2010; 4 (11): e895
23. Robert PY, Bourcier T, Meddeb-Ouertani A, et al. Efficacy assessment of azithromycin 1.5%eye drops versus tobramycin 0.3% on clinical signs of purulent bacterial conjunctivitis [in French]. J FrOphtalmol 2010Apr; 33 (4): 241-8
24. Laboratoires Thea. Clinical efficacy and safety of T1225 versus tobramycin 0.3% eye drops in the treatment of purulent bacterial conjunctivitis of children [ClinicalTrials.gov identifier NCT01155999]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www. clinicaltrials.gov [Accessed 2012 Jan 23]
25. Laboratoires Thea. Efficacy and safety assessment of Azyter- eye drops (T1225) in patients with blepharitis [ClinicalTrials.gov identifier NCT01089608]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov [Accessed 2011 Dec 14]